Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

We analyzed association of the levels of VEGFA, RAF1, and mTOR gene expression in the tissue of clear-cell renal cell carcinoma (ccRCC) with tumor metastasizing. Significant association with metastases was found only for VEGFA gene: OR=6.641, 95%CI=2.111-20.696. The risk of metastasis associated with reduced expression of VEGFA gene — 2.467, 95%CI=1.238-4.915. An association of VEGFA gene expression with the time to the metastasis appearance was revealed (p=0.0005). Reduced expression of the VEGFA gene is associated with reduction of the time to metastasis appearance; the median of this time is shifted from 46 to 2 months. Analysis of tumor samples with reduced expression of the VEGFA gene revealed association of increased expression of RAF1 (p=0.003) and mTOR genes (p=0.038) with metastasis.

作者简介

N. Apanovich

Research Center for Medical Genetics

Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow

M. Peters

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow

P. Apanovich

Research Center for Medical Genetics

Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow

A. Markova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow

B. Kamolov

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow

V. Matveev

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation; M. V. Lomonosov Moscow State University

Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow; Moscow

A. Karpukhin

Research Center for Medical Genetics

编辑信件的主要联系方式.
Email: karpukhin@med-gen.ru
俄罗斯联邦, Moscow

补充文件

附件文件
动作
1. JATS XML

版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2018